Medical cannabis programs are often discussed as legal frameworks, but at their core they are healthcare access systems. A patient receives a clinical evaluation, a physician determines whether cannabis is appropriate for their condition, and the state issues credentials that allow access through licensed dispensaries. The physician sits at the center of every step. How a state designs that physician’s role tells you a great deal about how the program functions in practice.
Arkansas and Oklahoma offer two of the most instructive examples in the country. Both rejected adult-use recreational legalization at the ballot box (Arkansas’s Issue 4 in 2022 and Oklahoma’s State Question 820 in 2023), and both have built sizable medical-only programs since. But they take notably different approaches to who qualifies and how physicians evaluate them. Understanding those differences is useful not only for patients in either state, but for any clinician or pharmacist whose patients are considering medical cannabis as part of their care.
Arkansas: A Defined-Condition Approach
Arkansas voters approved Amendment 98 in November 2016, establishing one of the first medical cannabis programs in the Southern United States. The Arkansas Department of Health (ADH) administers the program, which now serves more than 115,000 active patients as of May 2026, roughly 3.8% of the state’s population.
Arkansas takes a structured, list-based approach to qualification. A patient must be diagnosed with one of 18 specific qualifying conditions, including cancer, glaucoma, HIV/AIDS, Crohn’s disease, ulcerative colitis, PTSD, severe arthritis, fibromyalgia, ALS, Alzheimer’s disease, Tourette’s syndrome, peripheral neuropathy, hepatitis C, severe nausea, seizures, severe and persistent muscle spasms, cachexia (wasting syndrome), and intractable pain (defined as pain that has not responded to conventional treatment for at least six months). The list can be expanded through a formal petition process to ADH.
Only Arkansas-licensed Doctors of Medicine (MD) and Doctors of Osteopathic Medicine (DO) may sign the written certification form. Nurse practitioners and physician assistants are not authorized. The certification is valid for 30 days from the date signed, after which the patient must submit it to ADH along with a $50 application fee. Card processing typically takes up to 14 days. Telehealth evaluations are permitted under Arkansas Medical Board rules for telehealth, which has meaningfully expanded access for patients in rural counties. Patients seeking to start the certification process can connect with qualified Arkansas medical marijuana doctors through state-compliant telehealth platforms.
Once approved, Arkansas patients may purchase up to 2.5 ounces from a licensed dispensary every 14 days. Home cultivation is not permitted. Members of the Arkansas National Guard and the United States military are statutorily prohibited from holding a registry card.
Oklahoma: A Discretionary Approach
Oklahoma’s program, established by State Question 788 in 2018, takes a markedly different position. There is no fixed list of qualifying conditions. The statute instructs that a medical marijuana recommendation must be issued “according to the accepted standards a reasonable and prudent physician would follow when recommending or approving any medication.” In practical terms, this places the qualification decision in the hands of the certifying physician rather than a state-published condition list. It functions closer to how prescribers typically handle off-label use of approved medications: clinical judgment, documented in the medical record, applied to the individual patient.
The result has been one of the largest medical cannabis programs in the country. Oklahoma had roughly 322,000 active patients as of late 2025, after peaking at nearly 387,000 in 2022. Many new patients obtain an Oklahoma cannabis card by telehealth, an option the state has supported since the program launched.
A significant change took effect on January 1, 2026. Under Senate Bill 1066 (passed in 2025), physicians in Oklahoma must now register with the Oklahoma Medical Marijuana Authority (OMMA) and complete medical cannabis education requirements before they can issue patient recommendations. Physicians who are not registered with OMMA can no longer legally certify patients. The intent of the legislation is to ensure that any physician issuing recommendations has a baseline familiarity with cannabis pharmacology, dosing considerations, and patient counseling needs. It is a meaningful evolution from the program’s earlier, more permissive structure, and it brings Oklahoma closer to the kind of credentialing approach used in pharmaceutical prescribing.
What Patients in Both States Should Know
Regardless of which state administers the program, a quality medical cannabis evaluation should look much like any other clinical visit. The physician reviews medical history, current medications, prior treatments attempted, and the patient’s symptoms before determining whether cannabis is appropriate.
Disclosing every current medication is particularly important. Cannabinoids interact with the cytochrome P450 (CYP) enzyme system, which metabolizes a substantial portion of commonly prescribed medications. The clinical literature has documented potential interactions across several medication classes.
Warfarin, the oral anticoagulant, is the most well-characterized example. THC has been shown to inhibit the CYP2C9 enzyme responsible for warfarin metabolism. And case reports have documented elevated international normalized ratio (INR) values. Bleeding events in patients who initiated cannabis use without a corresponding warfarin dose adjustment. Antiepileptic medications, particularly clobazam, also show consistent evidence of pharmacokinetic interaction, primarily because cannabidiol (CBD) inhibits CYP3A4 and CYP2C19. Tacrolimus and other calcineurin inhibitors used in transplant patients carry similar concerns. SSRIs metabolized through CYP2C19 (such as citalopram and escitalopram) may interact with CBD. There is the additional consideration of additive sedation when cannabis is combined with antidepressants, opioids, or benzodiazepines.
These interactions do not mean cannabis is categorically incompatible with these medications. They do mean that a thorough medication review at the certification visit. And continued communication with the patient’s primary care provider, are essential. Patients should also be encouraged to discuss any new cannabis use with their pharmacist. Who can identify interaction risks at the point of dispensing and recommend monitoring where appropriate.
Why the Physician-Mediated Model Matters
Whether a state uses a defined condition list (as Arkansas does) or a discretionary clinical judgment standard (as Oklahoma does). The presence of a licensed physician in the certification process creates a documented care pathway. Patient records are generated, medication histories are reviewed, and accountability is preserved. Oklahoma’s recent move under SB 1066 to require physician registration. And cannabis-specific education reflects a continued trend toward strengthening clinical oversight rather than relaxing it.
For patients, this framework matters because medical cannabis is most useful. When integrated into ongoing care rather than treated as an unsupervised consumer product. For practitioners, including pharmacists who counsel patients on potential interactions. It provides a structure for communication that simply does not exist in unregulated markets.
Arkansas and Oklahoma demonstrate that there is no single template for designing medical cannabis access. There are credible reasons to favor either approach. What both states share is the recognition that patient safety. And program legitimacy rest on a qualified clinician at the center of every certification.